Hypovase 500microgram tablets

Country: United Kingdom

Language: English

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Active ingredient:

Prazosin hydrochloride

Available from:

Pfizer Ltd

ATC code:

C02CA01

INN (International Name):

Prazosin hydrochloride

Dosage:

500microgram

Pharmaceutical form:

Oral tablet

Administration route:

Oral

Class:

No Controlled Drug Status

Prescription type:

Valid as a prescribable product

Product summary:

BNF: 02050400; GTIN: 5013457019681

Patient Information leaflet

Page 1 of 6
PACKAGE LEAFLET: INFORMATION FOR THE USER
HYPOVASE
®
0.5 MG AND 1 MG TABLETS
(prazosin hydrochloride)
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor or pharmacist.

This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even if
their signs of illness are the same as yours.

If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side effects not
listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Hypovase is and what it is used for
2.
What you need to know before you take Hypovase
3.
How to take Hypovase
4.
Possible side effects
5.
How to store Hypovase
6.
Contents of the pack and other information
1.
WHAT HYPOVASE IS AND WHAT IT IS USED FOR
Hypovase contains the active substance prazosin hydrochloride, which
is one of a group of medicines called
alpha-blockers.
It is usually used to treat high blood pressure (hypertension). It may
also be used to treat heart failure, painful
cold fingers (Raynaud’s Disease) or mild enlargement of the prostate
gland (prostatic hyperplasia) in men.
In patients with high blood pressure (hypertension) Hypovase works by
relaxing blood vessels so that blood
passes through them more easily. It can be used alone or in
combination with other drugs used to treat
hypertension.
In patients with heart failure, Hypovase works by relaxing the main
blood vessels of the heart, allowing the
heart to pump blood more easily. Hypovase is usually used in heart
failure when other drugs are either no
longer working or have not worked at all.
In patients with Raynaud’s Disease the treatment relaxes blood
vessels in the hands, so blood can reach the
fingers more easily. This helps to prevent coldness and stiffness.
In patients with enlargement of the prostate gland the treatment is
taken to treat poor and/o

Summary of Product characteristics

OBJECT 1
HYPOVASE TABLETS 0.5MG
Summary of Product Characteristics Updated 12-Jun-2017 | Pfizer
Limited
1. Name of the medicinal product
Hypovase 0.5 mg tablets
2. Qualitative and quantitative composition
Prazosin hydrochloride equivalent to 500 micrograms prazosin base,
based on potency of 93.1 % base
activity.
For the full list of excipients, see section 6.1.
3. Pharmaceutical form
Tablets.
White and round marked "Pfizer" on one side.
4. Clinical particulars
4.1 Therapeutic indications
_Hypertension: _Hypovase is indicated in the treatment of all grades
of essential (primary) hypertension and
all grades of secondary hypertension of varied aetiology. It can be
used as the initial and sole agent or it
may be employed in a treatment regimen in conjunction with a diuretic
and/or other antihypertensive drug
as needed for proper patient response.
_Congestive heart failure: _Hypovase may be used alone or added to the
therapeutic regimen in those
patients with congestive heart failure who are resistant or refractory
to conventional therapy with diuretics
and/or cardiac glycosides.
_Raynaud's phenomenon and Raynaud's disease: _Hypovase is indicated
for the symptomatic treatment of
patients with Raynaud's phenomenon and Raynaud's disease.
_Benign prostatic hyperplasia: _Hypovase is indicated as an adjunct in
the symptomatic treatment of
urinary obstruction caused by benign prostatic hyperplasia (BPH). It
may therefore be of value in patients
awaiting prostatic surgery.
4.2 Posology and method of administration
Posology
_Hypertension:_ The dosage range is from 500 micrograms – 20 mg
daily. It is recommended that therapy
be initiated at the lowest dose, 500 micrograms, twice or three times
daily for three to seven days, with
the starting dose administered in the evening. This dose should be
increased to 1 mg twice or three times
daily for a further three to seven days. Thereafter, the daily dose
should be increased gradually as
determined by the patient's response to the blood pressure lowering
effect. Most patients are